Research Topics
Genomes and Genes
| Sherven SharmaSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunityLi X Zhu
University of California Los Angeles Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 1690, USA
J Immunol 170:3585-91. 2003..We report that sigma(1) receptor ligands, including cocaine, augment tumor growth through an IL-10 dependent mechanism...- Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinomaSherven Sharma
Department of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA Lung Cancer Research Program, David Geffen School of Medicine at UCLA, 37 131 Center for Health Sciences, 0833 LeConte Avenue, Los Angeles, CA 90095 1690, USA
Hum Gene Ther 14:1511-24. 2003.... - SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10Sherven Sharma
Department of Medicine, UCLA Lung Cancer Research Program, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Mol Cancer 2:22. 2003..We have previously shown that SLC/CCL21-mediated anti-tumor responses are accompanied by significant induction of IFNgamma and the CXC chemokines, monokine induced by IFNgamma (MIG/CXCL9) and IFNgamma-inducible protein-10 (IP-10/CXCL10)... - Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunitySeok-Chul Yang
Department of Medicine, University of California Los Angeles Lung Cancer Research Program and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, 90095, USA
Clin Cancer Res 10:2891-901. 2004..In vivo depletion of IP-10/CXCL10, MIG/CXCL9, or IFN-gamma significantly reduced the antitumor efficacy of DC-AdCCL21. These findings provide a strong rationale for the evaluation of DC-AdCCL21 in cancer immunotherapy... - Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responsesSherven Sharma
Department of Medicine, Lung Cancer Research Program, David Geffen School of Medicine, University of California Los Angeles, 10833 LeConte Avenue, Los Angeles, CA 90095 1690, USA
J Immunol 175:813-9. 2005..These findings provide a strong rationale for additional evaluation of the capacity of COX-2 inhibitors to enhance vaccination responses against cancer... - Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancerSherven Sharma
Department of Medicine, Lung Cancer Research Program, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 1960, USA
Cancer Res 65:5211-20. 2005..Transfer of Treg cells or administration of PGE2 to mice receiving COX-2 inhibitors reversed these effects. We conclude that inhibition of COX-2/PGE2 suppresses Treg cell activity and enhances antitumor responses... - EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer modelSven Hillinger
Department of Medicine, University of California, Los Angeles Lung Cancer Research Program, 90095 1690, USA
J Immunol 171:6457-65. 2003..These findings provide a strong rationale for further evaluation of ELC/CCL19 in tumor immunity and its use in cancer immunotherapy... - Tumor cyclooxygenase 2-dependent suppression of dendritic cell functionSherven Sharma
University of California Los Angeles School of Medicine Wadsworth Pulmonary Immunology Laboratory, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
Clin Cancer Res 9:961-8. 2003..We conclude that inhibition of tumor COX-2 expression or activity can prevent tumor-induced suppression of DC activities... - Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cellsKaren Riedl
Department of Medicine, UCLA Lung Cancer Research Program, 37 131 CHS, David Geffen School of Medicine at UCLA, 10833 LeConte Avenue, Los Angeles, CA 90095 1690, USA
Mol Cancer 2:35. 2003..In order to develop DC-based cancer therapies for intratumoral injection that could promote tumor antigen uptake and presentation in situ, we constructed and characterized an adenoviral vector that expresses human CCL-21 (AdCCL-21)... - Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancerKostyantyn Krysan
David Geffen School of Medicine at UCLA, Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-1690, USA
Chest 125:140S. 2004 - COX-2-dependent stabilization of survivin in non-small cell lung cancerKostyantyn Krysan
UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
FASEB J 18:206-8. 2004..In accord with these findings, survivin and COX-2 were frequently upregulated and co-expressed in human lung cancers in situ... - Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosisLing Zhang
Department of Pathology, David Geffen School of Medicine at UCLA and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90095, USA
J Biol Chem 279:28315-9. 2004..Thus, PKC-delta may play a critical role in the pathogenesis of pulmonary fibrosis and may serve as a molecular target for therapeutic intervention to suppress fibrosis... - Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancerMehis Pold
Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
Cancer Res 64:6549-55. 2004..Thus, these findings show that COX-2 augments the stimulatory arm of the IGF axis... - Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer modelsSherven Sharma
Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
Methods Mol Med 75:711-22. 2003 - Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancerFelicita Baratelli
UCLA Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Los Angeles, CA 90095, USA
J Transl Med 6:38. 2008..These results have provided the rationale to generate a clinical grade adenoviral vector encoding CCL-21 for ex vivo transduction of human DC in order to assess intratumoral administration in late stage human lung cancer... - Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cellsFelicita Baratelli
Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center and Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Immunol 175:1483-90. 2005..Finally, PGE2 up-regulated FOXP3 at both mRNA and protein levels and enhanced FOXP3 promoter activity. This is the first report indicating that PGE2 can modulate FOXP3 expression and T reg function in human lymphocytes... - PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cellsFelicita Baratelli
Jonsson Comprehensive Cancer Center and Division of Pulmonary and Critical Care Medicine, UCLA Geffen School of Medicine, 37-131 CHS, 10833 Le Conte Ave, Room 37-131 CHS, Los Angeles, CA 90095, USA
J Leukoc Biol 78:555-64. 2005..These findings suggest that PGE2-dependent regulation of survivin is important in modulating apoptosis resistance in human DC... - Cocaine modulates cytokine and enhances tumor growth through sigma receptorsBrian Gardner
Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA
J Neuroimmunol 147:95-8. 2004..We conclude that sigma(1) receptor ligands, including cocaine, augment tumor growth via a cytokine-dependent, receptor-mediated mechanism that involves regulation of T helper 1/T helper 2 cytokine balance... - IL-20, an anti-angiogenic cytokine that inhibits COX-2 expressionNathalie Heuzé-Vourc'h
Division of Pulmonary and Critical Care Medicine, Department of Medicine, UCLA, Los Angeles, CA, USA
Biochem Biophys Res Commun 333:470-5. 2005..IL-20-mediated inhibition of PMA-induced angiogenesis occurs through the COX-2 regulatory pathway. Altogether our findings revealed that IL-20 is a negative modulator of COX-2/PGE(2) and inhibits angiogenesis... - Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinomaSeok-Chul Yang
Department of Medicine, Lung Cancer Research Program, University of California at Los Angeles, CA 90095-1960, USA
Cancer Res 66:3205-13. 2006.... - Proinflammatory mediators upregulate snail in head and neck squamous cell carcinomaMaie A St John
Division of Head and Neck Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
Clin Cancer Res 15:6018-27. 2009..Herein we investigate the mechanisms by which interleukin-1beta (IL-1beta) might contribute to Epithelial-Mesenchymal Transition (EMT) in HNSCC... - IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancerXiaoyan Cui
Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, and Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Biochem Biophys Res Commun 343:995-1001. 2006..Overall, our studies demonstrate that IL-4 has the capacity to inhibit COX-2 mRNA transcription in NSCLC cells and the inhibition of PGE(2) appears to be predominately COX-2 dependent... - Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrixFelicita E Baratelli
Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, and the Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Immunol 173:5458-66. 2004..These findings indicate that PGE2-dependent enhancement of TIMP-1 production causes reduced migration of DC through ECM... - Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistanceKostyantyn Krysan
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
J Thorac Oncol 3:107-10. 2008..Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors... - Multifaceted roles of cyclooxygenase-2 in lung cancerKaren Riedl
UCLA Lung Cancer Research Program, Department of Medicine, 37-131 CHS, David Geffen School of Medicine at UCLA, 10833 LeConte Avenue, Los Angeles, CA 90095-1690, USA
Drug Resist Updat 7:169-84. 2004..In addition, delineation of how COX-2-dependent genes modulate the malignant phenotype will provide novel insights in lung cancer pathogenesis... - Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent mannerKostyantyn Krysan
UCLA Lung Cancer Research Program of Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1690, USA
Cancer Res 65:6275-81. 2005..Importantly, these findings suggest that COX-2 overexpression may contribute to EGFR inhibitor resistance in NSCLC... - Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into non-small cell lung cancer xenograftsMin Qin
Department of Medicine, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90073, USA
Clin Cancer Res 9:4992-9. 2003..CONCLUSIONS: These studies indicate CAR expression is predictive for more efficient gene transfer into NSCLC cells in vitro and in vivo but is not sufficient to achieve uniform transduction by Group C Ad vectors in vivo... - IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancerAsa Andersson
Department of Medicine, University of California Los Angeles Lung Cancer Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Immunol 182:6951-8. 2009..IL-7 decreased regulatory T Foxp3 as well as cell suppressive activity with a reciprocal increase in SMAD7. These results indicate that IL-7 induces CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer... - Inflammation and lung carcinogenesis: applying findings in prevention and treatmentKatherine A Peebles
David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, UCLA Lung Cancer Research Program, CA, USA
Expert Rev Anticancer Ther 7:1405-21. 2007..These newly discovered molecular mechanisms in the pathogenesis of lung cancer provide novel opportunities for targeted therapy and prevention in lung cancer... - Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinomaJane Yanagawa
Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine, 10833 Le Conte Avenue, 37 131 CHS, Los Angeles, CA 90095 1690, USA
Clin Cancer Res 15:6820-9. 2009..However, other important Snail-dependent malignant phenotypes have not been fully explored. Here, we investigate the contributions of Snail to the progression of non-small cell lung cancer (NSCLC)... - Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growthUpendra K Kar
Department of Biological Chemistry, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
PLoS ONE 6:e18758. 2011..We are evaluating a non-DC based approach which utilizes vault nanoparticles for intratumoral CCL21 delivery to mediate antitumor activity in lung cancer... - Cyclooxygenase-2 in lung cancerSteven M Dubinett
Lung Cancer Research Program, UCLA Jonsson Comprehensive Cancer Center, Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, Calif, USA
Prog Exp Tumor Res 37:138-62. 2003 - Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancerJenny T Mao
Department of Medicine, David Geffen School of Medicine at UCLA, 37 131 CHS, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095
Clin Lung Cancer 7:30-9. 2005..These preclinical data suggesting the antineoplastic effect of COX-2 inhibitors provide the basis for several ongoing pilot clinical trials to determine the feasibility of COX-2 inhibition in chemoprevention of bronchogenic carcinoma... - CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasisJudong Pan
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Immunol 176:1456-64. 2006.... - Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancerMariam Dohadwala
Lung Cancer Research Program of the University of California at Los Angeles Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
Cancer Res 66:5338-45. 2006..Thus, blocking PGE(2) production or activity may contribute to both prevention and treatment of NSCLC... - Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cellsNathalie Heuzé-Vourc'h
University of California at Los Angeles Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90095, USA
Cancer Res 63:766-70. 2003..Unresponsiveness of COX-2 to IL-10 is due to the deficiency of IL-10Ralpha on the surface of NSCLC cells. Our findings highlight a novel mechanism contributing to maintenance of elevated COX-2 and PGE(2) in the lung tumor environment... - Methanandamide increases COX-2 expression and tumor growth in murine lung cancerBrian Gardner
UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California 90095-1690, USA
FASEB J 17:2157-9. 2003..These results suggest that methanandamide augments tumor growth by a cannabinoid receptor-independent pathway that is associated with the up-regulation of COX-2... - The potential and rationale for COX-2 inhibitors in lung cancerKostyantyn Krysan
David Geffen School of Medicine at UCLA, Lung Cancer Research Program, 37-131 CHS, 10833 Le Conte Avenue, Los Angeles, California 90095-1690, USA
Anticancer Agents Med Chem 6:209-20. 2006.... - EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cellsMing Liu
Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095, USA
Am J Respir Cell Mol Biol 37:578-88. 2007..These findings emphasize the central role of EGFR signaling in COX-2 induction by TGF-beta1 and suggest that inhibition of EGFR signaling should be investigated further for lung cancer prevention... - CAR mediates efficient tumor engraftment of mesenchymal type lung cancer cellsMysore S Veena
Department of Surgery, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
Lab Invest 89:875-86. 2009..These data suggest that if the mesenchymal cell phenotype is an accurate measure of an undifferentiated and invasive state, then CAR expression may be more closely aligned with this phenotype of lung cancer cells... - Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatmentJay M Lee
Division of Cardiothoracic Surgery, Department of Surgery, UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Crit Rev Oncol Hematol 66:208-17. 2008..The understanding of molecular mechanisms involved in inflammation and lung carcinogenesis provide insight for new drug development that target reversible, non-mutational events in the chemoprevention and treatment of lung cancer... - Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanismRaj K Batra
Department of Medicine and The Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, University of California at Los Angeles and Veterans Administration-Greater Los Angeles Health Care System, Los Angeles, California 90095, USA
Cancer Res 63:642-6. 2003..We conclude that non-small cell lung cancer-derived soluble factors promote apoptosis in activated lymphocytes by an IKK-dependent pathway... - Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenaseSaswati Hazra
Department of Medicine, Division of Pulmonary, Lung Cancer Research Program and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
Mol Pharmacol 71:1715-20. 2007..Together, these findings indicate that it is possible to use a clinically available pharmacological intervention to suppress tumor-derived PGE(2) by enhancing catabolism rather than blocking synthesis... - Role of CXCR3 ligands in IL-7/IL-7R{alpha}-Fc-mediated antitumor activity in lung cancerAsa Andersson
Department of Medicine, UCLA Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, California, USA
Clin Cancer Res 17:3660-72. 2011..We evaluated the utility of chimeric ?c homeostatic cytokine, IL-7/IL-7R?-Fc, to restore host APC (antigen presenting cell) and T cell activities in lung cancer... - The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in boneSeth C Gamradt
Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Anticancer Res 25:107-15. 2005..This treatment had no effect on the osteolytic activity of PC-3 cells. CONCLUSION: These findings suggest that the progression of osteoblastic metastases induced by human prostate cancer cells may be limited by COX-2 inhibitors... - CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancerRobert M Strieter
Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 900 Veteran Avenue, 14 154 Warren Hall, Los Angeles, CA 90024 1922, USA
Ann N Y Acad Sci 1028:351-60. 2004..These findings may ultimately lead to clinical strategies to target CXC chemokines in non-small cell lung cancer... - Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cellsMin Qin
David Geffen School of Medicine at UCLA and Division of Pulmonary and Critical Care Medicine, Veterans Administration Greater Los Angeles Health Care System, 111Q, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA
Am J Respir Cell Mol Biol 32:211-7. 2005..This improvement in transduction of CAR-deficient cells by FGF2-Ad persisted in vivo. These data justify the need for an improved FGF2-Ad vector for clinical use in CAR-deficient lung cancer... - Cyclooxygenase 2-dependent regulation of antitumor immunity in lung cancerSherven Sharma
Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
Methods Mol Med 75:723-36. 2003 - Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cellsLing Zhang
Division of Pulmonary and Critical Care Medicine, University of California Los Angeles and Veterans Affairs Greater Los Angeles Healthcare System, California 90073, USA
Cancer Res 63:5065-72. 2003.... - Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistanceBao Hoang
David Geffen School of Medicine, University of California, Los Angeles, USA
Blood 107:4484-90. 2006..These results indicate a selective induction of cox-2 in MM cells containing RAS mutations, which results in heightened binding to extracellular matrix protein and chemotherapeutic drug resistance... - Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasionMariam Dohadwala
Lung Cancer Research Program of the UCLA Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
J Biol Chem 277:50828-33. 2002..Thus, blocking PGE2 production or activity by genetic or pharmacological interventions may prove to be beneficial in chemoprevention or treatment of NSCLC... - Smoking and lung cancer: the role of inflammationTonya Walser
Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine, 37 131 CHS, 10833 Le Conte Avenue, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1690, USA
Proc Am Thorac Soc 5:811-5. 2008..Full definition of these pathways will afford the opportunity to intervene in specific inflammatory events mediating lung tumorigenesis and resistance to therapy... - Myeloid suppressor cells and immune modulation in lung cancerMinu K Srivastava
University of California Los Angeles and Veterans Affairs Greater Los Angeles, CA, USA
Immunotherapy 4:291-304. 2012..Specific genetic signatures in lung cancer modulate the activities of MDSCs and impact tumor progression. Targeting MDSCs may have a long-term antitumor benefit and is at the forefront of anticancer therapeutic strategies... - Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieuRay M Bernal
Department of Medicine, The University of California at Los Angeles (UCLA)/ Wadsworth Pulmonary Immunology and Gene Medicine Laboratory, Los Angeles, CA 90073, USA
Clin Cancer Res 8:1915-23. 2002..g., within the extracellular matrix of solid tumors) the concentrations of secreted (or shed) CAR may be high enough to effectively compete with Ad gene delivery... - Chemokines: can effector cells be redirected to the site of the tumor?Steven M Dubinett
Department of Medicine, University of California Los Angeles Lung Cancer Research Program, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Cancer J 16:325-35. 2010..We review several areas of chemokine importance in tumor immunity and discuss the experimental evidence that is leading to the clinical use of this cytokine family in new treatment approaches for patients with cancer... - Identifying obstacles to viral gene therapy for lung cancer. Malignant pleural effusions as a paradigmRaj K Batra
Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System, Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
Methods Mol Med 75:545-59. 2003 - IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosisMin Huang
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1690, USA
J Clin Invest 109:931-7. 2002..The antifibrotic activities of IL-7 merit further basic and clinical investigation for the treatment of pulmonary fibrosis... - Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4Saroj K Basak
Division of Pulmonary and Critical Care, Department of Medicine, UCLA School of Medicine, Los Angeles 90095 1690, USA
Blood 99:2869-79. 2002..We conclude that systemic therapy with the combination of rGM-CSF/rIL-4 provides a new approach for generating DCs in vivo... - The Role of PPARgamma in the Cyclooxygenase Pathway in Lung CancerSaswati Hazra
UCLA Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
PPAR Res 2008:790568. 2008..Understanding the mechanisms underlying these effects may be helpful for designing anticancer therapies. This article summarizes recent research on the relationship between (PPARgamma), TZDs, and the COX-2/PGE2 pathways in lung cancer... - MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancerSherven Sharma
UCLA Lung Cancer Research Program, David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Los Angeles, CA 90095, USA
Expert Opin Biol Ther 11:987-90. 2011..Strategies that harness the immune system to react against tumors can be integrated with existing forms of therapy for optimal responses toward this devastating disease... - Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-betaBrian Gardner
Pulmonary Immunology Laboratory, Division of Pulmonary and Critical Care Medicine, 37-131 CHS, UCLA School of Medicine, Los Angeles, California 90073, USA
Biochem Biophys Res Commun 290:91-6. 2002..We conclude that one mechanism by which THC contributes to immune suppression is by stimulating an enhanced production of lymphocyte TGF-beta... - Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancerHarnisha Dalwadi
Lung Cancer Research Program, David Geffen School of Medicine, University of California at Los Angeles, 90095, USA
Clin Cancer Res 11:7674-82. 2005..These molecules affect numerous cellular pathways, including angiogenesis and apoptosis resistance, and, therefore, may act in concert in NSCLC... - A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cellsMin Qin
Department of Medicine and The Lung Cancer Research Program, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California at Los Angeles, California 90073, USA
Cancer Res 64:6377-80. 2004.... - Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancerKostyantyn Krysan
Division of Pulmonary and Critical Care, University of California at Los Angeles Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, 90095, USA
Cancer Res 64:6359-62. 2004..We conclude that COX-2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer... - Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherinKaren L Reckamp
Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, California, USA
J Thorac Oncol 3:117-24. 2008..Markers of EMT and tumor invasion were evaluated in patient serum from a phase I clinical trial investigating the combination of celecoxib and erlotinib in non-small cell lung cancer (NSCLC) patients...
Research Grants
- SLC/6Ckine Immunotherapy for CancerSherven Sharma; Fiscal Year: 2006..He is in an excellent scientific environment and will spend 100 percent effort to this endeavor. Work resulting in this environment will prepare Dr. Sharma for a successful independent career in basic cancer research. ..
- Novel Immune Pathways for Lung Cancer TherapySherven Sharma; Fiscal Year: 2009....
- Novel Immune Pathways for Lung Cancer TherapySherven Sharma; Fiscal Year: 2010....